Patients undergoing hip arthroplasty in the absence of prophylaxis for venous thromboembolic events (VTEs) are at high risk for experiencing postoperative VTEs. In the study reported here, we performed cost analyses involving efficacy and safety data from clinical trials evaluating fondaparinux and enoxaparin as VTE prophylaxis. Incremental cost-effectiveness ratios were calculated to determine cost per VTE avoided. In addition, cost per death averted and cost per life-year gained were calculated. Once-daily fondaparinux proved to be more cost-effective than once-daily enoxaparin 40 mg but less cost-effective than twice-daily enoxaparin 30 mg.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Link Between Venous and Arterial Thrombosis: Is There a Role for Endothelial Dysfunction?
Cells
January 2025
Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20125 Milan, Italy.
Venous thromboembolism (VTE) and arterial thrombosis (AT) are distinct yet closely related pathological processes. While traditionally considered separate entities, accumulating evidence suggests that they share common risk factors, such as inflammation and endothelial dysfunction (ED). This review explores the parallels and differences between venous and arterial thrombosis, with particular attention to the role of unprovoked VTE and its potential links to atherosclerosis and systemic inflammation.
View Article and Find Full Text PDFThe role of germline and somatic mutations in predicting cancer-associated thrombosis: a narrative review.
Curr Opin Hematol
January 2025
Amsterdam UMC, University of Amsterdam, department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam.
Purpose Of Review: Patients with cancer have an increased risk of venous thromboembolism (VTE). Guidelines suggest to use risk assessment tools to guide decisions about thromboprophylaxis, but current tools have modest discriminatory ability. Genetic information from the germline or tumor has the potential to improve VTE prediction.
View Article and Find Full Text PDFVenous thromboembolism (VTE) prevention program implementation in a community oncology practice: author response to Yang et al.
Lancet Reg Health Am
February 2025
University of Vermont Cancer Center, 89 Beaumont Ave, Burlington, VT, 05405, USA.
Age- and Sex-Specific Risks of Major Cardiovascular Complications and All-Cause Mortality Following Elective Hip and Knee Arthroplasty in the Netherlands: A Dutch Hospital Data Registry Study.
Arthroplast Today
February 2025
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
Background: Age and sex are well-known risk factors for cardiovascular complications and mortality following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Yet, stratified up-to-date absolute risk estimates, which are needed to optimize prevention, are lacking.
Methods: All Dutch patients who had a first primary THA and TKA for osteoarthritis between 2015 and 2021 were included.
Investigating the dual causative pathways linking immune cells and venous thromboembolism via Mendelian randomization analysis.
Thromb J
January 2025
Department of Vascular Surgery, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Background: Venous thromboembolism (VTE) is a common vascular disease with a significant global burden, influenced by multiple factors, such as genetic, environmental, and immune components. Immune responses and shifts in immune cell profiles are closely linked to the development and progression of VTE, yet current studies are limited by confounding factors and reverse causation. To address these limitations, this study uses Mendelian randomization to explore the causal relationship between immune cell traits and VTE, aiming to provide insights into underlying mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!